JP2005522228A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522228A5 JP2005522228A5 JP2003584732A JP2003584732A JP2005522228A5 JP 2005522228 A5 JP2005522228 A5 JP 2005522228A5 JP 2003584732 A JP2003584732 A JP 2003584732A JP 2003584732 A JP2003584732 A JP 2003584732A JP 2005522228 A5 JP2005522228 A5 JP 2005522228A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- expression
- nkcc1
- nucleic acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 239000000126 substance Substances 0.000 claims 16
- 102000047724 Member 2 Solute Carrier Family 12 Human genes 0.000 claims 14
- 108091006620 SLC12A2 Proteins 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 206010006187 Breast cancer Diseases 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 201000002528 pancreatic cancer Diseases 0.000 claims 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 239000003153 chemical reaction reagent Substances 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 230000002946 anti-pancreatic effect Effects 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 239000002853 nucleic acid probe Substances 0.000 claims 2
- 239000007790 solid phase Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0208332A GB0208332D0 (en) | 2002-04-11 | 2002-04-11 | Protien |
| GB0229875A GB0229875D0 (en) | 2002-12-21 | 2002-12-21 | Protein involved in cancer |
| PCT/GB2003/001589 WO2003087840A2 (en) | 2002-04-11 | 2003-04-11 | Protein involved in cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005522228A JP2005522228A (ja) | 2005-07-28 |
| JP2005522228A5 true JP2005522228A5 (enExample) | 2006-07-06 |
Family
ID=29252444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003584732A Pending JP2005522228A (ja) | 2002-04-11 | 2003-04-11 | 癌に関与するタンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20060088537A1 (enExample) |
| EP (1) | EP1497658A2 (enExample) |
| JP (1) | JP2005522228A (enExample) |
| AU (1) | AU2003227861A1 (enExample) |
| WO (1) | WO2003087840A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0422211D0 (en) * | 2004-10-06 | 2004-11-03 | Randox Lab Ltd | Method |
| DE102004052707A1 (de) * | 2004-10-22 | 2006-04-27 | Beiersdorf Ag | Schweiß verringernde kosmetische Zubereitung |
| TW200639253A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
| US9962424B2 (en) | 2007-04-27 | 2018-05-08 | Lantmännen As-Faktor Ab | Use of antisecretory factors (AF) for optimizing cellular uptake |
| US20090069189A1 (en) * | 2007-09-11 | 2009-03-12 | Cancer Prevention And Cure, Ltd. | Method of identifying proteins in human serum indicative of pathologies of human lung tissues |
| EP2396024A4 (en) * | 2009-02-11 | 2013-02-27 | Lantmaennen As Faktor Ab | USE OF ANTISECRREATORY FACTORS (AF) FOR OPTIMIZATION OF CELLULAR ABSORPTION |
| EP3444359A1 (en) | 2009-03-12 | 2019-02-20 | Cancer Prevention And Cure, Ltd. | Methods of identification of non-small cell lung cancer |
| WO2018187496A2 (en) | 2017-04-04 | 2018-10-11 | Lung Cancer Proteomics, Llc | Plasma based protein profiling for early stage lung cancer prognosis |
| US20200033347A1 (en) * | 2017-04-18 | 2020-01-30 | Universite Libre De Bruxelles | Biomarkers And Targets For Proliferative Diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01009369A (es) * | 1999-03-15 | 2003-06-06 | Eos Biotechnology Inc | Nuevos metodos para el diagnostico del cancer colorectal, composiciones, y metodos para seleccionar moduladores del cancer colorectal. |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US20030068636A1 (en) * | 2001-06-21 | 2003-04-10 | Millennium Pharmaceuticals, Inc. | Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| KR101008758B1 (ko) * | 2001-09-18 | 2011-01-14 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
-
2003
- 2003-04-11 JP JP2003584732A patent/JP2005522228A/ja active Pending
- 2003-04-11 US US10/510,508 patent/US20060088537A1/en not_active Abandoned
- 2003-04-11 EP EP03725321A patent/EP1497658A2/en not_active Withdrawn
- 2003-04-11 WO PCT/GB2003/001589 patent/WO2003087840A2/en not_active Ceased
- 2003-04-11 AU AU2003227861A patent/AU2003227861A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021167805A (ja) | SARS−CoV−2感染症を診断するための方法および試薬 | |
| JP2025133108A5 (enExample) | ||
| RU2013113439A (ru) | Идентификация опухолеассоциированных антигенов для диагностики и терапии | |
| JP2005504513A5 (enExample) | ||
| JP2015533788A5 (enExample) | ||
| JP2008517928A5 (enExample) | ||
| JP2009544284A5 (enExample) | ||
| DE69737788D1 (de) | Reagenzien und methoden zum nachweis von erkrankungen der brust | |
| JP2018518151A5 (enExample) | ||
| JP2014503180A5 (enExample) | ||
| JP2005522228A5 (enExample) | ||
| KR20120057562A (ko) | 피브린 및 피브리노겐 분해 생성물의 검출 및 관련된 제조 방법 및 암의 검출 및 모니터링을 위한 용도 | |
| JP2007523644A5 (enExample) | ||
| JP2004513614A5 (enExample) | ||
| JP2003527109A5 (enExample) | ||
| JP2007527995A (ja) | 分子上のエピトープの免疫検出のための試薬、キット及び方法 | |
| JP2007513873A5 (enExample) | ||
| JP5821198B2 (ja) | 抗il28b抗体及びこれを用いたil28bの測定方法 | |
| JP2008500833A5 (enExample) | ||
| JP7044721B2 (ja) | Hcvコア抗原の迅速な検出のための前処理法 | |
| CN109313201B (zh) | 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体 | |
| WO2014096386A1 (en) | Anti-hdac11 antibodies | |
| JP2005522229A5 (enExample) | ||
| JP2004515215A5 (enExample) | ||
| JP2008535855A5 (enExample) |